Psychedelic stocks are about to skyrocket.
Oregon legalized psilocybin mushrooms for therapeutic use when voters approved Measure 109 on November 4, 2020. Notably, other areas have decriminalized minor possession of psilocybin mushrooms, as well, including Denver, Colorado; Washington D.C.; and Somerville, Northampton, and Cambridge, Massachusetts. California is currently reviewing a bill to decriminalize both psilocybin and ecstasy.
This recent turn of events has created a tidal wave of publicly traded psychedelic companies and prompted many successful investors to jump head-first into the industry. What’s more, because the psychedelic industry is so young, there is ample room for new or small-time investors to get in on the game, as well.
Psychedelic Stocks and Market Trends
Psychedelics are an interesting phenomenon, offering a potential benefit for those who suffer from mental health issues, in particular. In fact, one early study suggests that large, controlled doses of psilocybin mushrooms or “magic mushrooms” may substantially decrease symptoms of anxiety and depression for more than six months after treatment.
Notably, mental health in the U.S. is an increasingly prevalent issue. According to Mental Health America, 19 percent of adults experienced mental health issues in 2017 and 2018, which is an increase of about 1.5 million people! Sadly, during the thick of COVID (January through September 2020), anxiety rates increased by 93 percent, and depression rates increased by 62 percent.
Taking this into account, many pharmaceutical companies view psychedelic stocks as a potential gold mine. After all, those who can bring their approved psilocybin products to market first will lead the pack in both reputation and sales. Consequently, numerous pharmaceutical companies have recently entered the psychedelic space, as have some Oregon-based treatment facilities and product distributors.
Going public helps psychedelic agencies secure the funding necessary to conduct proper clinical trials and bring regulated products to market.
Experts project that psychedelic stocks could be worth $6.85 billion by 2027 at a Compound Annual Growth Rate (CAGR) of 16.3 percent.
High-Profile Psychedelic Stocks Investors
After witnessing a massive cannabis industry boom, many high-profile investors have jumped head-first into psychedelic stocks. With stock prices low and potential gain high, even those who were apprehensive now understand the value of psychedelic investments. Here are four high-profile investors that have staked their claim in the psychedelic space.
Shark Tank’s Kevin O’Leary is a long-time businessman and founder of many investment firms, including O’Leary Funds, O’Leary Ventures, and ETF and investing. O’Leary has also invested considerable funds into the psychedelic space, particularly into the company Mind Medicine (MindMed) Inc. His participation in the psychedelic stock market is especially noteworthy given his past opposition to marijuana investments.
According to O’leary, psychedelics are an attractive investment because they have vast problem-solving potential for many Americans suffering from mental illness and addiction. As he notes in this Business Insider article, “If psychedelic medicines such as psilocybin, LSD, and MDMA have the slightest potential to help restore America’s mental health, then so be it.”
Bruce Linton is the Founder and former CEO of Canopy Growth Corp, the world’s largest cannabis company as of April 2019. In September of 2019, Linton announced his new role as Director of the psychedelic company Mind Medicine. The company currently focuses on the mental health benefits of therapeutic psilocybin and MDMA. According to Linton, psychedelics likely possess “untapped value, which will only go to the people who are at the beginning and bold.”
PayPal Co-Founder Peter Thiel has invested $12 million into the psychedelic drug development company ATAI Life Sciences. The firm plans to acquire, incubate and develop psychedelic drugs to help treat mental health conditions like anxiety, depression, and addiction, which Thiel believes demands haste. Thiel told CNBC, “ATAI’s great virtue is to take mental illness as seriously as we should have been taking all illness all along… The company’s most valuable asset is its sense of urgency.”
Former Pfizer Executive and accomplished neuroscientist Michael Ehlers was recently named Strategic Advisor at Field Trip Psychedelics Inc. Field Trip is the world’s first legal psychedelics and psychedelic-assisted psychotherapy company and research center, and Ehlers is honored to be part of it. According to Ehlers, “psychedelics and psychedelic-assisted psychotherapy are promising new paradigms for the treatment of neuropsychiatric disorders.” He believes his role as Strategic Advisor can greatly help advance our understanding of psychedelic therapy.
Best Psychedelic Stocks to Watch
Aion TherapeuticAion Therapeutic is an international pharmaceutical company that uses Artificial Intelligence (AI) to create disease-specific cannabis and psilocybin formulations. The company filed four new patents in March 2021 focusing on the use of medicinal mushrooms for cancer patients.
Algernon Pharmaceuticals is a clinical stage company that looks for ways to re-purpose existing pharmaceuticals for new disease applications. They are currently researching DMT’s non-psychedelic potential for the recovery of brain tissue in stroke survivors.
ATAI Life Sciences
ATAI Life Sciences develops novel therapeutic drugs, including psychedelics, to help treat mental health conditions like depression, anxiety, traumatic brain injury, and PTSD. They are in the clinical stage of development, having raised considerable capital through their initial NASDAQ public offering, including $12 million from PayPal Co-Founder, Peter Thiel.
Awakn Life Sciences
Awakn Life Sciences is a biotech company that focuses on the research, development, and delivery of psychedelic therapeutics. They hope to use psychedelic medicines to treat depression, anxiety, PTSD, and depression. They’ve recently raised more than $225 million in funding through their initial NASDAQ public offering. As such, Awakn Life Sciences is one of the best publicly traded psychedelic companies to watch.
Better Plant Sciences
Better Plant Sciences is a vertically integrated company that focuses on plant-based wellness products. Their parent company, NeonMind Biosciences (formerly called Flourish Mushroom Labs) has confirmed that the biotech company will begin psilocybin clinical trials with plans to sell branded mushroom-based products to help support cognition, memory, immune system functioning.
BetterLife Pharma is a second-generation psychedelics company that develops commercial psychedelic products for distribution in the USA, Canada, Australia, and the European Union. They hope to use an LSD derivative to help treat severe forms of treatment-resistant depression. Notably, BetterLife Pharma is currently testing LSD in the pre-clinical stage for substance abuse treatment and plans to begin the next round of trials in 2022. They are also researching potential COVID-19 treatments.
Braxia Scientific develops psychedelic derivatives and operates multidisciplinary community-based clinics to help treat mental health disorders quickly and efficiently. They currently have clinics in Toronto, Mississauga, Ottawa, and Montreal. The recently launched Braxia Institute is now researching ketamine- and psychedelic-based therapy for patients suffering from treatment-resistant depression.
Bright Minds Biosciences
Bright Minds Biosciences researches serotonin system functioning to determine precise corelations between specific serotonin agonists and related mental health problems. They then use this information to develop superior first-generation compounds out of substances like psilocybin. The company recently applied for NASDAQ listing.
Captiva Verde Wellness
Captiva Verde Wellness is a cannabis company that recently joined the psychedelic space when after partnering with Mexican pharmaceutical company, Esmeralda. The global health and wellness company is now poised to distribute both psychedelic and non-psychedelic products directly to consumers, including large-scale quantities of micro-dosed mushroom products.
Clearmind Medicine develops psychedelic medicines to help treat mental health conditions like binge eating and alcohol abuse. One of their patents, an alcohol substitute, is approved in Europe and pending approval in the US, India, and China. Their second patent for binge behavior has already been approved in those same four locations.
Investment company, Codebase Ventures, helps investors diversify their portfolios by offering direst stakes companies like psychedelic company, Red Light Holland. They also focus on things like cryptocurrency and cannabis/CBD companies.
COMPASS Pathways is one of the most popular publicly traded psychedelic companies on the market. The psychedelic research company gained breakthrough therapy research approval through the FDA in 2018. Its first research program seeks to develop psilocybin therapy for those suffering from treatment-resistant depression. Late-stage clinical trials are currently happening in Europe and North America.
Core One Labs
(CSE:COOL, OTC Pink:CLABD)
Core One Labs is a biotech company that develops front-facing psychedelic medicines like thin-film oral strips. They also provide psychedelic-assisted psychotherapy to help treat mental health problems and addiction
Creso Pharma is a cannabis/hemp company specializing in enhanced cannabinoid bioavailability and absorption. They develop lifestyle products like their patent-pending water-soluble cannabinoid powder, and have recently joined the psychedelic space by acquiring Halucenex Life Sciences. They also plan to merge with Red Light Holland to build the HighBrid Lab.
CURE Pharmaceutical Holding
CURE Pharmaceutical Holding develops immediate- and controlled-release drug-delivery technology to help improve drug safety, efficacy, and patient experiences. They’ve recently added psychedelic-based drugs to their pipeline and created an oral film delivery system to accommodate those who have limited access to safe drinking water or have difficulty swallowing pills.
Cybin is a life science company dedicated to improving mental health through psychedelic therapy. Importantly, they employ technology-enhanced screening processes to ensure optimal medications and drug delivery systems to support long-term recovery. As such, they aim to address the underlying causes of mental health problems rather than treat the symptoms.
EGF Theramed Health
EGF Theramed Health frames itself as a pioneer in the psychedelic space by exploring and improving psychedelic delivery methods to help treat things like alcohol addiction, anxiety, PTSD, and depression. The FDA recently granted the company breakthrough status for its psychedelic research, suggesting that the compounds “preliminary clinical evidence indicate that the drug may demonstrate substantial improvement on a clinically significant endpoint(s) over available therapies.”
Ehave is a publicly traded psychedelic company that studies the cause of HPPD, or Hallucinogen-persisting perception disorder. Researchers believe that those who experience these persistent sensory disturbances resulting from past hallucinogenic drug experiences may have a genetic predisposition to the problem. As such, the company will conduct large-scale genetic analyses to determine who is at risk for the disorder.
Empower Clinics is a health and wellness brand that operates a multi-state network of clinics that focus on innovative mental health treatment options. With more than 165,000 patients in its care, the team seeks to improve mental health at scale using alternative treatment options like hemp-derived CBD and psilocybin therapy.
Entheon Biomedical is a biotech company working to develop psychedelic (ketamine) treatment options to aid in addiction recovery. Additionally, they hope to pinpoint the cause of substance abuse disorder using DMT to significantly reduce the occurrence of “untreatable” addiction.
Enveric Biosciences is a primarily cannabinoid-focused company. However, they recently acquired MagicMed Industries, thus launching them into the psychedelic space. The acquisition expands Enveric’s portfolio to include psychedelic compounds like psilocybin and DMT.
Field Trip Health
Field Trip Health is a clinical network throughout North America that delivers psychedelic-assisted therapy. Usually, treatment occurs through a series of sessions during which therapists prepare the patient, engage in psychedelic therapy, then integrate the experience. Their first ketamine clinic opened in Toronto, though they now have clinics in New York, Los Angeles, Chicago, Atlanta, Houston, and Amsterdam. Notably, former Pfizer Executive, Michael Ehlers, is Field Trip’s newly-appointed Strategic Advisor.
Field Trip Health, Inc.
Field Trip Health is a Canadian health company that operates clinics focused on psychedelic therapy and plant-based psychedelic research. The company hopes to open five clinics in its first year and have 75 clinics established by the end of 2023. There are currently three open Field Trip Health clinics that conduct ketamine-enhanced therapeutic sessions. Those clinics are located in Toronto, New York, and Los Angeles.
Filament Health is a psychedelic drug company that focuses on drug discovery and compound extraction technology to address a global mental health crisis. Importantly, they are currently conducting two FDA-approved clinical trials to test the efficacy of natural psychedelic compounds, including DMT, mescaline, harmaline, and more.
GH Research develops novel DMT therapy for those who suffer from treatment-resistant depression. This publicly traded psychedelic company has completed Phase 1 clinical trials in healthy volunteers, which seems to suggest significant improvement after a single dose of psychedelics. They are currently conducting Phase 2 of their ongoing clinical trial to determine if a second higher dose produces a more substantial benefit.
Global Trac Solutions
Global Trac Solutions is a publicly traded digital media company that focuses on emerging psychedelic medicine. The newly-launched platform features news and information about the psychedelic industry.
Goodness Growth Holdings
Though primarily a multi-state cannabis company, Goodness Growth Holdings recently entered the psychedelic space when it filed a US patent for virtual reality technology for use during psychedelic therapy. Importantly, the scalable platform allows clinicians to customize virtual environments to help optimize the therapeutic experience.
Graph Blockchain recently acquired Shroom Street for $1M. The company plans to integrate blockchain technology with product-tracking tools in the psychedelic industry.
Havn Life Sciences
Havn Life Sciences researches and develops psilocybin medicines following Health Canada’s Section 56 exemption. This publicly traded psychedelic company researches, extracts, formulates, and delivers psychedelic medicines as an innovative approach to mental health. Notably, company advisors include many popular Canadian cannabis players, including Vic Neufeld of Aphria.
Hollister Biosciences is a cannabis company that recently joined the psychedelic space when it acquired AlphaMind Brands for $1.2M. The company hopes to build a portfolio of legal mushroom-based health products in addition to its extensive cannabis listings.
KetamineOne Capital operates plant-based healthcare clinics throughout North America to help treat mental health and emotional pain. Importantly, their ketamine-enhanced treatments help provide life-changing mental health services through wearable technologies that track key vitals before, during, and after psychedelic therapy. The company has been studying psychedelic therapies for over 23 years. Consequently, the company is well-equipped with cutting-edge technologies, research techniques, and seasoned industry experts.
Levitee Labs is a multidisciplinary wellness company that seeks to prevent, restore, and improve mental health conditions through novel psychedelic therapies. Their innovative, evidence-based model uses psychedelic medicines to reduce inefficiencies within our current mental healthcare system, including improved access to mental health support for underserved populations.
Lobe Sciences includes a team of scientists, engineers, and physicians dedicated to improving brain health with psychedelic medicines. They currently have five patents pending, including medicines and devices that can help treat PTSD and Traumatic Brain Injury. Their current focus is on both Psilocybin and MDMA therapy as well as patent-pending medical devices that deliver these compounds through the nasal cavity.
M2Bio Sciences is a biotech company that develops cannabinoid and psilocybin-based medicines via its wholly-owned subsidiary company, MJ MedTech. Notably, the company issues commercial products under the brand names Liviana, Medspresso, Dr. AnnaRx, and Handcrafted Delights. Their innovative therapies seek to assist those suffering from mental health disorders, Alzheimer’s and Parkinson’s Disease.
Mind Cure Health
Mind Cure Health combines technology and research to revolutionize the mental wellness journey. They synthesize psychedelic compounds and develop treatment protocols that target specific brain receptors for enhanced mental health. They also offer a compatible software called iSTRYM to help both patients and clinicians navigate the complex mental health journey.
Mind Cure Health Inc.
Mind Cure Health Inc. is a Canadian biotech company that produces and distributes mushroom powders and supports synthetic psychedelic research. The company boasts its multi-dimensional approach to therapy through psychedelic medicines, clinician support, and mobile technology.
Mind Medicine is a biotech company backed by many high-profile investors. The company is developing psychedelic therapies, including psilocybin, DMT, MDMA, and LSD, to potentially help treat addiction and mental health issues.
Mind Medicine offers breakthrough psychedelic medicines and technology to help patients achieve sustained mental healing. The company was the first psychedelic company to make its public debut on Toronto’s NEO stock exchange in 2020. Consequently, since then, many well-known investors have taken an interest in the company, including Founder and former Canopy Growth Corp CEO, Bruce Linton and Shark Tank’s Kevin O’Leary. As such, Mind Medicine is one of the most popular publicly traded psychedelic companies on the market today.
Mindset Pharma (CSE:MSET,OTCQB:MSSTF)
Toronto-based drug company Mindset Pharma creates novel psychedelic compounds to help treat neurological and psychiatric disorders. They hope to build a large library of psychedelic intellectual property to help address neuropsychiatric disorders.
Mydecine Innovations Group
Mydecine Innovations Group is a nature-based medicine group designed to help combat mental illness. The company is currently developing an artificial intelligence/machine learning-based drug screening process. Their aim is to more efficiently expand our knowledge of psychedelic substances. Though Mydecine Innovations stock prices are exceptionally low at this time (currently under $0.50 per share), the technology that backs the company will soon explode its market value.
Mydecine Innovations Group (OTC Pink:MYCOF,NEO:MYCO)
NewLeaf Brands acquired Mydecine Group for $1.2M to create the Mydecine Innovations Group in June 2020. Notably, Mydecine Innovations Group is a biotech and life sciences company that develops medical-grade products from both psychedelic and non-psychedelic mushrooms. Health Canada has certified the company to cultivate, extract, distribute, and analyze various mushroom compounds for treating certain mental health conditions, particularly PTSD.
NeonMind Biosciences (CSE:NEON,OTCQB:NMDBF)
NeonMind Biosciences develops consumer goods to help promote weight loss with psilocybin. The company hopes to deliver a line of functional foods to address obesity, noting the high worldwide prevalence coupled with psilocybin’s tendency to curb appetite. They currently offer an expansive coffee line in Canada and hope to expand distribution to a global market soon.
New Wave Holdings (CSE:SPOR,OTC Pink:TRMNF)
New Wave Holdings is an investment firm that focuses on three different psilocybin markets: recreational, natural (health and beauty), and mental health. They currently have two production facilities in Jamaica and established export agreements with Brazil and the Netherlands.
Novamind operates a wide network of psychedelic clinics, research sites, and therapeutic retreats. Specifically, they specialize in ketamine-assisted therapy as a means of innovative, evidence-based mental health care. Additionally, they hope to add MDMA (for PTSD), psilocybin (for depression), LSD, and other psychedelics to their offerings. Chuck Rifici, Canopy Growth co-founder, is on the company’s board of directors.
Numinus Bioscience is a healthcare company licensed through Health Canada to test, sell, and distribute psychedelic substances like Ketamine, Psilocybin, Psilocin, DMT, LSD, and Mescaline. They currently have a single facility in British Columbia, Canada, and plan to establish more locations throughout Canada soon.
Numinus Wellness is a Canadian company that engages cultivation, research, development, and testing of both cannabis and certain psychedelics. Numinous also supports practitioners and facilitates guided psychedelic experiences, while developing treatment protocols for substances like ketamine, LSD, and psilocybin. These psychedelic stocks currently trade at less than $1.00 per share, though this is likely to increase substantially as the sector builds momentum.
Nutritional High International
Nutritional High International renamed High Fusion in Sepember 2021, recently purchased the psychedelic business Psychedelic Science, thus earning the cannabis company’s way into the psychedelic space. The company researches psychedelic cacti for treating pain, anxiety, insomnia, and obesity. They are currently developing their products for FDA approval, after which they will file patents to protect their future market share.
Optimi Health develops functional mushroom-based formulas to promote positive emotional development. They operate two facilities in British Columbia where they cultivate and process therapeutic mushrooms. Notably, the company will soon launch commercial operations as they work to establish global leadership in the industry. They are currently seeking exemption through Health Canada to advance their psychedelic research.
Pharmadrug is an international drug company based out of Germany under the ownership of cannabis distributor Pharmadrug GmbH. However, they did not enter the psychedelic space until they acquired Super Smart, a Netherlands company that promotes the legal availability of psilocybin mushrooms in the country.
PharmaTher Holdings is a psychedelic biotech company focusing on ketamine therapy for depression, Parkinson’s Disease, and general pain. They are working to approve psychedelics for FDA approval, having already secured ketamine and esketamine, and are currently developing a patented microneedle patch for safer, more efficient psychedelic delivery.
PysBio Therapeutics develops therapeutic formulas from plants and fungi to help treat numerous mental health conditions. Notably, these biosynthetic psychoactive compounds promote mental health by helping the brain rewire trauma responses. Working with Miami University, PsyBio Therapeutics has developed proprietary technology to synthesize psilocybin and other active plant compounds for breakthrough mental health treatment.
Psyched Wellness is a Canadian health and wellness company that develops artisanal, medicinal mushroom supplements. Importantly, they have a strong focus on both environmental and societal sustainability with their organically farmed and Fair Trade products. They proudly boast their pure distilled psilocybin mushroom products for treating things like anxiety, stress, pain, and insomnia.
Psyence Group is a biotech company that researches and develops psilocybin-based medicines to help treat stress, depression, anxiety, PTSD, grief, and bereavement. They develop their products specifically for clinics and research institutions within multiple global jurisdictions. They also operate one of the forest federally approved psilocybin cultivation facilities in Southern Africa.
Red Light Holland
Red Light Holland is a psychedelics company that produces and distributes “magic” truffles in the Netherlands. Notably, these are recreational psychedelics. However, the company plans to upgrade to medical-grade truffles pending certification through the European Union.
Revive Therapeutics is a cannabinoid pharmaceutical company that focuses on rare inflammatory issues. The company joined the psychedelics space when it purchased Psilocin Pharma, which already produces unique psilocybin formulas. Moving forward, Revive Therapeutics will continue to study psilocybin’s effect on various diseases and disorders. They are also exploring the benefit of Bucillamine against infectious diseases like COVID-19.
Roadman Investments joined Psychedelic Insights to create a line of psychedelic clinics as a pharmaceutical-free alternative to mental healthcare. No doubt, this is just another one of many publicly traded psychedelic companies to watch soar.
Seelos Therapeutics is a bio-pharmaceutical company that develops therapeutics to help treat Central Nervous System Disorders like ALS, Parkinson’s Disease, and more. The company received fast-track designation in 2019 for its ketamine therapy for those experiencing suicidal ideation and major depressive disorder.
Silo Wellness is a wellness company that focuses on psychedelics and functional mushrooms. They were also the first to announce a patent-pending psilocybin nasal, which the company hopes will address the most common issues consumers experience. Particularly, the nasal spray offers a better flavor, accurate dosing, and minimal nausea. Additionally, Silo Wellness offers guided psychedelic wellness retreats to help people release trauma and reach their higher selves. The Jamaican retreats last for about a week and involve yoga, meditation, and guided psychedelic experiences.
Tryp Therapeutics investigates the effectiveness of certain psychedelic compounds for treating rare conditions like fibromyalgia. They are currently Phase 2 ready for the expedited development of psilocybin-based pharmaceuticals for those with treatment-resistant health conditions.
Wesana Health Holdings
(Wesana Health Holdings (CSE:WESA,OTCQB:WSNAF))
Wesana Health Holdings develops psilocybin-based therapeutics to help treat neurological, psychological, and mental health problems. Additionally, the company also acquired Psychedelitech (PsyTech) through which they will promote their SaaS program Tovana Solutions. Notably, PsyTech Connect is the industry’s largest network of professional psychedelic practitioners.
How Risky are Psychedelic Stocks?
The cannabis industry is one of the fastest-growing sectors globally, with sales more than tripling from 2014 to 2018. Though many were apprehensive about investing in such a volatile industry as cannabis, the attitude towards psychedelic investments is changing.
Most investors appreciate the proposed therapeutic potential of psychedelics rather than the recreational market. Much of this appeal centers around the way psychedelics affect mental health, particularly as it may enhance therapy for more long-term results. Specifically, whereas cannabis may alter the symptoms of mental discomfort, psychedelics could help address the cause of mental health issues. Given the growing prevalence of mental health disorders in America, many investors and medical experts are eager to get the ball rolling in the right direction.
Having said that, the psychedelic industry may require special attention from investors and advocates alike. Notably, public perception about psychedelics is not where it needs to be. For example, a recent Hill-HarrisX poll found that 65 percent of adults believe that “psychedelic substances do not have medical uses.” Consequently, the most significant factor affecting the legal trajectory of magic mushrooms is education and easy access to psilocybin resources.
It’s also important to note that FDA approval may be challenging, even with successful phase 3 trials. However, continuous positive clinical research can help improve public perception, which voters can use to sway more widespread psychedelic legislation.
More About Psychedelco and Psychedelic Stocks
At Psychedelco, our mission is to educate the public and raise awareness about psilocybin and psychedelic therapies. Though we still have a lot to learn, what we’re finding is too exciting not to share.
Please, like and share our content to help support our mission.
What psychedelic stocks are you investing in?